Mounjaro vs. Compounded Tirzepatide: What Patients Need to Know

Medical Disclaimer: The information provided in this article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before making any decisions about your health or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

For individuals seeking effective solutions for weight management or type 2 diabetes, tirzepatide has emerged as a powerful option. This medication is available as the FDA-approved brand-name drugs Mounjaro and Zepbound, and also as compounded tirzepatide. Understanding the key differences between these options is crucial for making informed healthcare decisions.

What is Tirzepatide?

Tirzepatide is a novel medication that acts as a dual agonist for both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This unique mechanism of action helps to regulate blood sugar levels, reduce appetite, and slow gastric emptying, leading to significant improvements in metabolic health and weight reduction [1].

FDA-Approved Tirzepatide: Mounjaro and Zepbound

Eli Lilly manufactures tirzepatide under two distinct brand names, each with specific FDA approvals:

Mounjaro (tirzepatide): This medication is FDA-approved for adults with type 2 diabetes mellitus to improve blood sugar control. While not its primary indication, many patients using Mounjaro also experience significant weight loss as a beneficial side effect [2].
Zepbound (tirzepatide): This is the FDA-approved option for chronic weight management in adults. It is prescribed for individuals with obesity (Body Mass Index [BMI] of 30 or greater) or those who are overweight (BMI of 27 or greater) and have at least one weight-related comorbidity, such as high blood pressure, high cholesterol, or obstructive sleep apnea [3].

Both Mounjaro and Zepbound have undergone rigorous clinical trials to demonstrate their safety and efficacy. The SURMOUNT clinical trial program, for instance, has provided robust data on tirzepatide's effectiveness in weight management.

In the SURMOUNT-1 trial, which involved adults without diabetes, participants receiving tirzepatide once weekly achieved substantial and sustained reductions in body weight. Those on the highest dose (15 mg) experienced an average weight reduction of 20.9% over 72 weeks [4]. The SURMOUNT-4 trial further highlighted the importance of continued treatment, showing an average body weight reduction of 25.3% from week 0 to week 88 for participants on tirzepatide, compared to a 9.9% reduction in the placebo group [5].

Common side effects reported in these trials were primarily gastrointestinal, including nausea, vomiting, diarrhea, and constipation. These were generally mild to moderate in severity and often improved as treatment continued [4].

Compounded Tirzepatide: What You Need to Know

Compounded medications are custom-prepared by pharmacies for individual patients. While compounding serves a vital role in healthcare for specific needs (e.g., allergies to inactive ingredients, unique dosage forms), compounded tirzepatide presents several critical considerations:

Lack of FDA Approval: Compounded tirzepatide is not FDA-approved [7]. This is a fundamental difference from Mounjaro and Zepbound. The FDA's approval process ensures that a drug is safe, effective, and manufactured according to strict quality standards. Compounded drugs do not undergo this same level of scrutiny [7].
Variable Quality and Purity: The purity, potency, and sterility of compounded tirzepatide can vary significantly. The FDA does not verify the quality of ingredients or the manufacturing processes of compounded drugs [7]. Eli Lilly, the patent holder for tirzepatide, does not supply the active pharmaceutical ingredient (API) to compounding pharmacies [8]. This raises questions about the source and quality of the tirzepatide API used in compounded versions.
Potential Safety Risks: Without FDA oversight, there is an increased risk of receiving a product with incorrect dosages, contaminants, or unverified ingredients. The FDA has issued warnings about fraudulent compounded GLP-1 products and the potential for serious health risks [9].

Why Choose Fig Health for Your Weight Management Journey?

Fig Health is dedicated to providing accessible, medically supervised weight management solutions. We prioritize your safety and well-being by connecting you with licensed healthcare professionals who can assess your health profile and determine the most appropriate treatment plan, including access to GLP-1 medications like compounded semaglutide and tirzepatide, when clinically indicated and in full compliance with regulatory guidelines.

We believe in complete transparency, especially when it comes to pricing. With Fig Health, you'll find:

No Membership Fees: We eliminate hidden costs, so you only pay for your medication and care.
Transparent Pricing: Compounded semaglutide is available for $145-$175/month, and compounded tirzepatide for $233-$279/month.
Personalized Care: Our healthcare providers offer individualized guidance to support your weight loss journey.

Take the first step towards a healthier you with Fig Health's supportive and transparent approach.

Call to Action: Start Your Online Visit with Fig Health

Conclusion

Mounjaro and Zepbound are FDA-approved medications containing tirzepatide, rigorously tested for safety and efficacy in managing type 2 diabetes and chronic weight. Compounded tirzepatide, while offering an alternative, lacks FDA approval and the associated assurances of quality, purity, and consistent manufacturing. Patients considering tirzepatide for weight loss should be fully aware of these distinctions and discuss all options with a qualified healthcare provider.

References

[1] Prevention Clinics. "Mounjaro, Zepbound, and Tirzepatide: Understanding the Differences." Prevention Clinics, Feb 8, 2025. https://www.preventionclinics.com/post/mounjaro-zepbound-and-tirzepatide-understanding-the-differences
[2] U.S. Food and Drug Administration. "MOUNJARO (tirzepatide) injection, for subcutaneous use." FDA Prescribing Information, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
[3] U.S. Food and Drug Administration. "ZEPBOUND (tirzepatide) injection, for subcutaneous use." FDA Prescribing Information, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf
[4] Jastreboff, A. M., et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, vol. 387, no. 3, 2022, pp. 205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[5] Aronne, L. J., et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial." JAMA, vol. 331, no. 1, 2024, pp. 38-48. https://jamanetwork.com/journals/jama/fullarticle/2812936
[6] U.S. Food and Drug Administration. "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." FDA Drug Alerts and Statements, Apr 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
[7] GoodRx. "Is Compounded Tirzepatide Safe?" GoodRx, https://www.goodrx.com/classes/gip-receptor-glp-1-receptor-agonists/compounded-tirzepatide
[8] Eli Lilly and Company. "Open Letter Regarding the Use of Mounjaro® (tirzepatide) and Zepbound® (tirzepatide)." News Release, Jan 4, 2026. https://lilly.gcs-web.com/news-releases/news-release-details/open-letter-regarding-use-mounjaror-tirzepatide-and-zepboundr
[9] U.S. Food and Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." FDA Drug Alerts and Statements, Jun 15, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss